

1           **Evolution of synchronous bilateral breast cancers provide insights into interactions**  
2   **between host, tumor and immunity.**

3  
4           **Authors**

5           Anne-Sophie Hamy<sup>1,2</sup>, Judith Abecassis<sup>2,3</sup>, Lauren Darrigues<sup>4</sup>, Cecile Laurent<sup>2</sup>, François  
6           Zaccarini<sup>4</sup>, Benjamin Sadacca<sup>2</sup>, Myriam Delomenie<sup>4</sup>, Enora Laas<sup>4</sup>, Odette Mariani<sup>5</sup>, Thanh  
7           Lam<sup>6</sup>, Beatriz Grandal<sup>2,4</sup>, Marick Lae<sup>5,7</sup>, Ivan Bieche<sup>8,9</sup>, Sophie Vacher<sup>9</sup>, Jean-Yves Pierga<sup>1</sup>,  
8           Etienne Brain<sup>1</sup>, Celine Vallot<sup>10,11</sup>, Judicael Hotton<sup>12</sup>, Wilfrid Richer<sup>11,13</sup>, Joshua Waterfall<sup>11,14</sup>,  
9           Fabien Reyal<sup>2,4</sup>

10          **Affiliations**

11          1Department of Medical Oncology, Institut Curie, Université de Paris, 75005 Paris, France

12          2Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research  
13          Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris,  
14          75005 Paris, France

15  
16          3INRIA, Université Paris-Saclay, CEA, Palaiseau, 91120, France

17          4Department of breast, gynecological and reconstructive surgery, Institut Curie, Université de  
18          Paris, 75005 Paris, France

19          5Departement of tumor biology, Institut Curie, Paris 75005, France

20          6Department of Gynecology and Obstetrics, Geneva, University Hospitals, 30 bd de la Cluse,  
21          1205 Geneva, Switzerland

22          7Department of Pathology, Centre Henri Becquerel, INSERM U1245, UNIROUEN,  
23          University of Normandie, 76038 Rouen, France

24          8INSERM U1016, Faculty of Pharmaceutical and Biological Sciences, Université de Paris,  
25          75005 Paris, France

26          9Pharmacogenomics Unit, Department of Biopathology, Institut Curie, 75005 Paris, France

27          10CNRS UMR3244, Institut Curie, PSL University, Paris, France

28          11Translational Research Department, Institut Curie Research Center, PSL Research  
29          University, Paris 75005, France

30          12Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-  
31          Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France Department of  
32          Surgical Oncology, Institut Godinot, 1 Rue du Général Koenig, 51100 Reims, France 75005,  
33          France

34 <sup>13</sup>PSL Research University, Institut Curie Research Center, INSERM U932, Paris, France

35

36 <sup>14</sup>INSERM U830, Institut Curie, PSL University, Paris, France

37 \*: Both authors contributed equally to this manuscript

38

39 **Correspondence:**

40 [fabien.reyal@curie.fr](mailto:fabien.reyal@curie.fr)

41 [joshua.waterfall@curie.fr](mailto:joshua.waterfall@curie.fr)

42 **Abstract (219 words)**

43

44 Synchronous bilateral breast cancer (sBBC) occurs after both breasts have been affected by  
45 the same germline genetics, reproductive life factors and environmental exposures for  
46 decades. It represents an opportunity to decipher the complex interplay between host, tumor,  
47 immune system and response to neoadjuvant chemotherapy (NAC). On a cohort of 17575  
48 BCs treated between 2005 and 2012, sBBCs (n=404) were associated with less aggressive  
49 proliferative patterns and higher rates of luminal breast cancers (BCs) when compared with  
50 unilateral BCs (n=17171). The left and right tumors were concordant for the majority of  
51 clinical and pathological features. Tumor pairs of concordant BC subtype were more frequent  
52 than pairs of discordant BC subtype, with notably a particularly high frequency of pairs of  
53 luminal BCs. Intriguingly, both the levels of tumor infiltrating lymphocytes (TILs) and the  
54 response to NAC were modified by the subtype of the contralateral tumors. Whole exome  
55 sequencing and RNAseq analyses revealed that left and right tumors were independent from a  
56 somatic mutation and transcriptomic point of view, while primary tumors (PT) before NAC  
57 and specimens with residual disease (RD) after NAC were more closely related. The analysis  
58 of the TCR repertoire identified very little overlap between patients, while common clones  
59 were shared in bilateral tumors within each patient. After NAC, the TCR repertoire of RD was  
60 enriched and expanded with clones edited by the contralateral PT.

61

62

## 63 **Introduction**

64

65 Bilateral breast cancers (BBCs) represent 2% to 11% of breast cancers<sup>1-3</sup> and their incidence  
66 is increasing due to advances in breast cancer imaging<sup>4</sup>. This entity includes both  
67 synchronous bilateral breast cancers (sBBCs) and metachronous bilateral breast cancer  
68 (mBBCs), according to the length of time between the two diagnoses, with typical cut-offs  
69 ranging from 3 to 12 months after diagnosis of the first tumor. sBBCs are associated with a  
70 poorer survival than unilateral cancer in several studies<sup>2,5,6</sup>. In a study of 123,757 women  
71 with a primary BC diagnosed from 1970 to 2000, the cumulative breast cancer specific  
72 mortality was 45% for women with sBBC and 33% (p<0.001) in case of unilateral breast  
73 cancer<sup>2</sup>. Beyond familial history of breast cancer, which is more frequent in women with  
74 BBC, neither synchronous nor metachronous breast cancer is associated with strong genetic  
75 determinants and only 5% of patients with BBC carry *BRCA1* or *BRCA2* mutations<sup>5</sup>. Hence,  
76 per the 2020 NCCN guidelines, bilaterality is not considered as a factor clinically indicating  
77 genetic testing, but it may be considered in patients diagnosed with BBC between the age of  
78 50 and 65 years<sup>7</sup>.

79 From the genomic point of view, several studies have investigated clonal relationships  
80 between BBCs, with the majority reaching the conclusion that most of – if not all - BBCs  
81 were independent events<sup>8-14</sup>. These studies used several methods to address the question of  
82 the origin of BBCs, including X chromosome inactivation analysis, comparisons of allelic  
83 imbalance patterns<sup>10,12,15</sup>, or the distribution of p53 mutations<sup>11,16</sup>, karyotyping<sup>17</sup>, and  
84 comparative genomic hybridization (CGH)<sup>14,18</sup>. Many of these studies were based on  
85 technologies with limited resolution for assessing clonality. Recently, analyzing a targeted  
86 sequencing panel of 254 genes including all known driver genes in BC, Begg and colleagues<sup>19</sup>  
87 investigated the clonality of 30 synchronous and 19 metachronous BBC pairs, and found that  
88 only 3 out of 49 pairs harbored strong molecular evidence supporting a clonal relationship  
89 between BBCs. However, only one pair of sBBCs was interpreted as clonally related (2  
90 shared mutations out of 3 mutations identified), leaving the question of the independence  
91 between sBBCs still open.

92

93 The immune microenvironment and especially the role of tumor-infiltrating lymphocytes  
94 (TILs) in BC has been studied extensively in the last decade. The drivers of BC  
95 immunosurveillance derive from both (i) tumor-intrinsic characteristics; and/or (ii) extrinsic  
96 factors related to the host or the environment. Among endogenous tumor characteristics,

97 molecular features (BC subtype, proliferative patterns), expression of human leukocyte  
98 antigen (HLA)-class I, tumor mutational burden <sup>20</sup>, and activation of particular cellular  
99 signaling pathways <sup>21</sup> have been found to be associated with immune infiltration. Extrinsic  
100 factors including host characteristics (gender <sup>22</sup>, age <sup>23</sup>, body mass index), environment  
101 (tobacco, alcohol), nutritional factors, diet, commensal microbiota, physical activity, and  
102 hormonal exposure have been studied less extensively. Even if our understanding of the  
103 immune microenvironment has improved, it remains unclear to what extent anti-tumor  
104 immunity is driven by the tumor, by the host, or the interaction between the host and the  
105 tumor.

106

107 Neoadjuvant chemotherapy (NAC) is currently administered to patients with locally advanced  
108 breast cancers. Beyond increasing the rate of breast-conserving surgery, it serves as a test of  
109 *in vivo* chemo-sensitivity, and the analysis of residual tumor burden may help understanding  
110 resistance to treatment. Molecular BC subtypes and the density of tumor-infiltrating immune  
111 cells are both considered as important predictive and prognostic factors for optimal risk  
112 stratification and treatment individualization. Many studies have reported associations  
113 between high levels of TILs at diagnosis and better response to NAC <sup>24,25</sup>, and better  
114 prognosis in both neoadjuvant and adjuvant chemotherapy, particularly for triple negative  
115 BCs (TNBC) and *HER2*-positive BC <sup>26</sup>.

116

117 sBBCs occur after both breasts have been affected by the same germline genetics,  
118 reproductive life factors and environmental exposures for several decades. Two tumors  
119 arising concomitantly in a host mimic a model where (i) *extrinsic factors* are almost fully  
120 shared by the same host; (ii) *intrinsic factors* are specific to the tumor of each side; (iii) the  
121 *immune tumoral microenvironment* resulting of the interaction between the same host and two  
122 different tumors can be compared. In the case where these tumors are treated by NAC, sBBCs  
123 represent a unique opportunity to decipher the interactions between tumor, microenvironment,  
124 and response to treatment.

125

126 In this study, we describe on a large institutional cohort of sBBCs the relationships between  
127 factors related to host, tumor phenotypes, levels of TILs and response to NAC. In addition, we  
128 identified a rare resource of highly selected tumors, *i.e.*, sBBCs treated by NAC, and  
129 performed whole exome sequencing (WES), copy number variation, and RNA sequencing

130 (RNAseq) to draw a comprehensive analysis of somatic alterations, the immune

131 microenvironment and the tumor evolution under treatment.

132

## 133 **Results**

### 134 ***Patient and tumor characteristics***

135 Out of 17575 BC patients in our institutional clinical database, 404 patients had synchronous  
136 bilateral BC (2.3%) (FigS1). Patients with sBBC were slightly older at diagnosis (60.4 *versus*  
137 58.2 years,  $p=0.001$ ) and had a higher mean BMI (25.6 *versus* 24.7,  $p<0.001$ ) than patients  
138 with unilateral breast cancer. A lower proportion of grade 3 (20.9% *versus* 29.4%,  $p<0.001$ ),  
139 tumors of TNBC (7.7% *versus* 11.1%) or *HER2*-positive (6.1% *versus* 11.4%,  $p<0.001$ )  
140 subtype, or with lymphovascular invasion (21.2% *versus* 28.4%,  $p<0.001$ ) were observed in  
141 bilateral tumors than in unilateral BCs (TableS1 and FigS2). ER and PR staining percentages  
142 were lower in unilateral than in bilateral BCs. Out of 313 patients with invasive sBBCs, most  
143 of the tumors were luminal (n=538, 87.6%), whereas TNBC (n=44, 7.2%) and *HER2*-positive  
144 BCs (n=32, 5.2%) were rare (TableS2). Overall, paired sBBC tumors shared more common  
145 characteristics than expected by chance (TableS3): the majority (84.7%) of the tumor pairs  
146 were concordant regarding clinical and pathological patterns, notably regarding BC subtype  
147 (Fig1A). In luminal tumors, ER and PR staining intensity of stained cells were lower when the  
148 pair of tumors was discordant than when the pair of tumors was concordant (Fig1B-C).

149

### 150 ***Baseline immune infiltration***

151 Immune infiltration levels before treatment were available for 277 pairs of tumors. TIL levels  
152 were positively associated notably with a younger age, palpable, higher grade tumors, of no  
153 specific histological type, with a higher number of nodes involved and the presence of  
154 lymphovascular invasion (TableS4). TILs were higher in TNBC and *HER2*-positive BCs than  
155 in luminal tumors. Interestingly, the relationship between TIL levels and BC subtype showed  
156 a systemic effect, *i.e.*, it was affected by the subtype of the contralateral tumor. In luminal  
157 BCs, stromal (Str) TIL levels were lower when the subtype of the contralateral tumor was  
158 concordant than when it was discordant, and the same trend was observed for intratumoral  
159 (IT) TILs (Fig1D-E). Conversely, in TNBCs, the IT TIL levels were lower when the subtype  
160 of the contralateral tumor was concordant than when it was discordant. The interaction test  
161 was highly significant ( $P_{interaction}=0.0006$ ), indicating that the impact of tumor subtype on IT  
162 immune infiltration was significantly modified by the concordance of the BC subtype of the  
163 tumor pair it belonged to. This suggests that TIL levels are not purely determined by local  
164 tumor microenvironment properties.

165

166 ***Response to NAC***

167 Out of 313 patients, 50 patients received neoadjuvant chemotherapy (NAC). Twenty two out  
168 of 100 tumors reached pathological complete response (pCR). In pairs with concordant tumor  
169 types, the pCR rate was higher for TNBC tumors than for luminal BC (50% *versus* 9%)  
170 (Fig1F-G). As was seen for TIL levels, these pCR rates showed a systemic effect when the  
171 contralateral tumor subtype was discordant. The pCR rate was higher in luminal BCs when  
172 the contralateral pair was of different subtype (9% *versus* 22%); while the opposite pattern  
173 was found in TNBCs (50% *versus* 27%), and the interaction test was significant ( $P_{interaction}$   
174 =0.07), suggesting that the response to treatment was modified by the BC subtype of the  
175 contralateral tumor differentially in luminal and in TNBCs tumors.

176

177 ***Genome-scale analyses***

178

179 For 6 patients with sBBCs treated with NAC, frozen material of sufficient quality was  
180 available to perform tumor/normal whole exome sequencing (WES) and tumor RNA  
181 sequencing (RNAseq) in both left and right pre and post NAC samples (including one patient  
182 with a multicentric bilateral breast cancer) (FigS3, TableS5). Germline pathogenic mutations  
183 in BC predisposition genes were identified in four patients (*BRCA1*, n=2, *BRCA2*, n=2).  
184 Among the 14 primary tumors (PT), 9 were of luminal subtype and 5 were TNBCs. All  
185 patients received standard sequential anthracyclines-cyclophosphamide followed by taxanes.  
186 After NAC completion, 6 out of 14 tumors had residual disease (RD), while 8 tumors reached  
187 pCR.

188

189 ***Somatic single nucleotide and indel mutations***

190 Twenty tumor samples (pre-NAC: n =14; post-NAC: n=6) were profiled by WES and  
191 RNAseq and distant juxta-tumor samples were used for germline WES sequencing in each  
192 patient. A median of 151.5 somatic mutations were detected per tumor (PT: 161.5 *versus* RD:  
193 54), and a median of 3 mutations were annotated as potential drivers (splice site, nonsense,  
194 frameshift or non-synonymous SNVs in COSMIC census gene) in each sample (PT: 3.5  
195 *versus* RD: 3) (TableS6). Tumors that reached a pCR had a similar median number of  
196 mutations (median 195 (driver: 5)) to those who had RD (median: 84 (driver: 2.5) and no  
197 difference was seen according to BC subtype (luminal: 160 (driver: 3) *versus* TNBC: 182  
198 (driver: 4)).

199 The three most frequently mutated COSMIC genes were *TP53* (3 patients, 8 samples), *PTEN*  
200 (3 patients, 3 samples), and *ARID1A* (2 patients, 2 samples) (Fig2A). The majority of the  
201 remaining genes were mutated only in single patients, consistent with a high genetic diversity  
202 of mutations BC. No mutation was shared between the left and right side of the PTs from any  
203 patient, consistent with the contralateral tumors developing from independent clones (Fig2B).  
204 The majority of the mutations of a tumor were shared between a PT and its RD (median  
205 percentage of shared mutations in pairs of PT/RDs: 51.3%).

206

### 207 *Copy number alterations (CNAs)*

208 Copy number analysis of the WES profiles identified recurrent gains (8 out of 12 samples) at  
209 1q, 8q, 17q and recurrent losses (over 50% of the samples) at 4p, 8p, 6q, 13q, 16q and in a  
210 lesser extent 1p (FigS4). Most of the alterations were not shared between the left and the right  
211 side (Fig3A), while most of the CNAs were common between PT and RD (Fig3B).

212

### 213 *Mutational signatures*

214 We analyzed mutational signatures by deconvoluting the frequency of the 96 different  
215 possible trinucleotide substitutions against known signatures of mutation patterns <sup>27</sup>. We  
216 found that the four most abundant base substitution signatures were signature 3 (34%),  
217 signature 5 (17%), and signature 40 (10%) (Fig3C). Signature 3 is known to be associated  
218 with *BRCA1/2* mutations (Alexandrov et al., 2020) and its contribution was high (54%) in all  
219 tumors from patients carrying *BRCA* germline mutations (Patient #1, #2, #4, #6) (Fig3C).  
220 Furthermore, signature 3 was also found in the left tumor of patient #5 who carried a somatic  
221 *BRCA1* mutation, while it was absent from the right-side tumor which did not show any  
222 *BRCA1-2* mutations. Signatures 5, 40 and 1 are commonly found in diverse tumor types and  
223 are associated with aging and were generally found at consistent levels between bilateral  
224 tumor pairs. Similarities regarding mutational processes were lower within the left and right  
225 side of the PTs than within pairs of PT-RDs (Fig3D).

226

### 227 *Clonality and phylogenetic evolution*

228 We determined the phylogenetic evolution between the germline profile of the patient to the  
229 left and right primary tumors and ultimately to the residual disease if present (Fig4A-E and  
230 supplemental results). The number of clones identified in each tumor sample ranged from 2 to  
231 6. Genomic profiling found no common clones between bilateral primary tumors of the same  
232 patient, showing that these tumors arose through unrelated tumor evolution processes. Further



233 illustrating this, left and right tumors showed distinct evolution regarding the homologous  
234 recombination deficiency (HRD), with the emergence of a somatic mutation on the *BRCA1*  
235 gene in only one out of the two tumors of a patient (Fig1E).

236 For patient #3, for which we monitored evolution after NAC in both tumors in parallel, we did  
237 not observe any common clonal evolution after NAC. In all tumors, several clones  
238 disappeared under NAC (Fig4A and Fig4C, light turquoise clones; Fig4E grey clone),  
239 consistent with subclone specific responses to therapy. Finally, the majority of clones that  
240 emerged after NAC did not show identifiable additional genetic drivers, suggesting potential  
241 non genetic additional mechanisms could play a role in the tumor evolution under treatment.  
242 Altogether, these results suggest that left and right PTs are not clonally related and that their  
243 evolution under NAC does not converge to a common profile. Hence, RD is closer to its  
244 associated primary tumor than to its concomitant contralateral tumor.

245

#### 246 *Particular case of multicentric tumors*

247 One patient of the six had a bilateral multicentric tumor (Patient #6) in the context of a  
248 *BRCA2* pathogenic germline mutation. While the left and the right tumors shared no common  
249 mutations, the two tumors from each side shared a majority of common genetic alterations at  
250 both the substitution (Fig5A) and copy number levels (Fig5B). Mutation signature analyses  
251 demonstrated a dominant genomic HRD footprint (signature 3, Fig5C). On each side,  
252 phylogenetic reconstruction clearly indicated that multicentric tumors were clonally related,  
253 with one tumors evolving to a neighbor tumor through the extinction / emergence of  
254 particular subclones.

255

#### 256 *Transcriptomic alterations*

##### 257 Tumor clustering

258 We first performed unsupervised hierarchical clustering based on transcriptomic profile of the  
259 most variable genes. With the exception of tumor PT\_5L, the sample clustering first split by  
260 BC subtype (luminal and TNBCs) (FigS5), while gene clustering split the 2846 genes into  
261 four main clusters. The clustering first split samples into a group of luminal tumors and a  
262 group of TNBCs (with the exception of the ER weakly positive (+25%) luminal tumor PT5\_L  
263 clustering into the TNBC group). The group of luminal tumors was globally enriched in genes  
264 from cluster 1 (early and late response to estrogens); and a subset of luminal tumors were also  
265 enriched in genes from the cluster 2 (*TNF* signaling, myogenesis, epithelial mesenchymal  
266 transition). The majority of TNBC samples were enriched in genes from cluster 3 (G2M

267 checkpoints, E2F targets, cellular cycle). Genes from cluster 4 showed no clear enrichment in  
268 specific pathways and were expressed in complex patterns by both luminal and TNBC tumor  
269 subsets. Within each subgroup, the PT samples consistently clustered with their related RD  
270 rather than the tumor from the contralateral side. This suggests that beyond the well-known  
271 distinct gene expression profiles according to BC subtype, PT and RD are closer from a  
272 transcriptomic point of view than are left and right tumors from the same patient.

273

#### 274 Immune infiltration

275 We applied the CIBERSORT algorithm to deconvolute RNAseq expression profiles into 22  
276 subsets of immune subpopulations. Out of the 20 samples, the top 3 most abundant immune  
277 subpopulations were M2 macrophages (median: 32), CD4 memory resting T cells (median:  
278 26) and M1 macrophages (median: 11), while the majority of immune subpopulations was not  
279 identified at significant levels, whether in PT or RD (FigS6A). CD4 memory T cells and M2  
280 macrophages were increased in RD compared with PT (FigS6B); T follicular helper cells and  
281 M1 macrophages were significantly higher in TNBC than in luminal BCs, while resting mast  
282 cell levels were lower (FigS6C). At the patient level, we did not identify any additional  
283 patterns between the left and the paired right tumor (FigS7), nor between the PT and the  
284 paired corresponding residual disease (FigS8).

285 We compared the predicted immune contexture patterns between samples of the cohort using  
286 a dissimilarity index (FigS9). Analyzing the entire cohort, the dissimilarity was lower among  
287 the PT samples (blue area) than among the RD samples (orange area) (mean: 0.24 *versus*  
288 0.37,  $p=0.009$ ), while the greatest difference was seen between PTs samples compared with  
289 RDs samples (yellow area, mean = 0.49)

290 Analyzing paired data, the mean dissimilarity index was significantly lower between samples  
291 of the same side of patient 6 than between the remaining samples (red bordered squares, mean  
292 = 0.025), while the dissimilarity indices between the left and the right sides (green bordered  
293 squares, mean = 0.22), and between PT and related RDs (yellow bordered squared, mean =  
294 0.29) were not statistically different from the rest of the samples. These results suggest that  
295 the composition of the immune microenvironment is strongly driven by the treatment history  
296 (PT or RD), while the similarity between a tumor from one side or its contralateral side, or a  
297 given tumor and its paired post-chemotherapy sample is lower.

298

299

300 TCR sequencing analysis

301 To further investigate the T cell response to NAC and to compare infiltrating TCR repertoires  
302 in clonally distinct tumors within single patients, we extracted TCR beta CDR3 sequences  
303 from the RNAseq data, and 6708 clonotypes were identified in the whole cohort. Overall,  
304 89.4% were unique to individual samples (n=5994) (FigS10A), 10.2% were patient specific  
305 but shared by multiple samples (n=682), and only 32 clonotypes (0.5%) were identified in  
306 different patients (FigS10B).

307

308 150 clonotypes (2.2%) were found in VDJdb, a curated database of T-cell receptor sequences  
309 of known antigen specificity (FigS10C). The most common antigens for this subset were  
310 CMV and Influenza, but the wide majority of clonotypes were unique to a sample. Among  
311 135 clonotypes found both in PT and paired RD, the read count increased significantly after  
312 NAC ( $p=0.005$ ) (Fig6D).

313 The evolution under NAC of non-unique clones is summarized for each patient in Fig6. While  
314 the most common sharing relationships were between PT and matched RD (orange  
315 clonotypes) followed by left and right tumor, a subset of clones identified in an index PT were  
316 found in the contralateral RD (red clonotypes) or emerged *de novo* in both RD samples of the  
317 same patient (pink clonotypes).

318 Finally, common shared TCRs were extremely rare between individuals, and most of the TCR  
319 clonotypes of a tumor were unique. However, a shared TCR repertoire was identified between  
320 the left and right primary tumors. An enrichment of TCR repertoire after NAC was identified,  
321 including clonotypes deriving a from the contralateral primary tumor.

## 322 **Discussion**

323

324 In the current study, we conducted a large comprehensive overview of sBBCs, integrating  
325 clinical, pathological data and data on immune infiltration, together with genomic data  
326 generated using modern whole exome and RNA sequencing technologies. It provides  
327 important insights to understand the relationships between tumor, host, immunity and  
328 response to treatment.

329

330 First, we found no indication that sBBCs could be genomically related but rather we conclude  
331 that they represent two distinct and independent diseases occurring incidentally at the same  
332 time.

333 In line with previous studies<sup>28,29,30,31</sup>, we found a high concordance between the clinical and  
334 biological patterns within pairs of sBBCs. Notably, the proportion of luminal tumors was very  
335 high<sup>32,33</sup>, while *HER2*-positive BCs were rare as previously reported<sup>30</sup>. In our study, despite  
336 the frequent clinical and pathological concordance between the left and right tumors, we  
337 demonstrate clearly that these tumors were genomically independent in terms of mutations,  
338 copy number alterations, expression patterns, and clonal composition. This finding is in line  
339 with most published studies<sup>8,12,14,19</sup>, despite with older technologies. In line with previous  
340 works, we also identified genomically related profiles in multicentric tumors, thus confirming  
341 with modern technologies that multi-focal tumors often represent intramammary  
342 dissemination of a single breast cancer<sup>15,14,17,34</sup>. Overall, these results are consistent with the  
343 fact that the occurrence of sBBCs is explained by nongenetic factors<sup>35</sup>.

344

345 Second, we found that the immune infiltration was not purely determined by local tumor  
346 microenvironment properties, as TILs levels were different according to the BC subtype of  
347 the contralateral tumor. Published studies regarding immune infiltration in sBBCs is scarce, if  
348 any. Analyzing samples of sBBCs from 23 patients, one study found that nuclear grade was  
349 significantly associated with the number of FoxP3<sup>+</sup> positive TILs<sup>36</sup>. In the current work, we  
350 analyzed immune infiltration on a large number of sBBCs and confirmed that BC subtype was  
351 a master driver of immunosurveillance in BCs. We also found that immune infiltration was  
352 modified by the presence of a contralateral tumor: luminal BCs associated with a luminal  
353 contralateral BCs had lower str TIL levels than luminal BCs associated with a contralateral  
354 BCs of a different subtype. Similarly, a TNBC associated with a contralateral TNBC had  
355 higher IT TIL levels than TNBCs associated with a contralateral BC of a different subtype.

356 Several hypotheses can be drawn to explain this observation. First, the immune system might  
357 be activated by an index tumor, and immune cells activated by this process might spread to  
358 the contralateral tumor; resulting in differences in TIL levels. Second, as luminal BCs  
359 associated with a contralateral tumor of another subtype were associated with a lower degree  
360 of “luminalness” (as defined by ER and PR staining levels), we cannot exclude that the  
361 highest immune infiltration is derived from such patterns rather than from the presence of the  
362 contralateral tumor.

363

364 Third, the response to NAC was also significantly modified in the case of discordant  
365 contralateral tumor subtypes, as with TIL levels. Evidence regarding the influence of  
366 contralateral tumor on the response to treatment has been rarely described. In a cohort of 119  
367 patients enrolled in four German neoadjuvant trials, Reinisch and colleagues<sup>37</sup> reported that  
368 patients with BBCs had lower pCR rates than patients with unilateral BC (12.6% versus  
369 20.9%). These lower rates could partially be explained by the tumor characteristics, as the  
370 percentage of hormone receptor positive tumors was significantly higher in the indicator  
371 lesions of the sBBCs when compared with the unilateral cancer cohort. However, the response  
372 to NAC in sBBCs was lower after statistical adjustment for baseline parameters ( $p= 0.077$   
373 with a small number of pCR (13/119)). In our study, it remains unknown whether the  
374 difference of the rates of pCR according to the contralateral tumor are the consequence of  
375 different baseline immune infiltration levels, or if the contralateral tumor modifies *per se* the  
376 chemosensitivity of an index tumor.

377

378 Fourth, in tumors resistant to treatment and for which we could perform NGS analysis, the  
379 primary tumor and the residual specimen shared a large majority of SNVs and copy number  
380 aberrations, but the genomic profile did reveal important changes after NAC. Notably,  
381 resistant clones emerged and new potential driver mutations appeared in an independent  
382 manner on both sides. Hence, beyond a weak influence of the contralateral tumor on either  
383 immune infiltration and/or response to NAC, clonal evolution under NAC seems specific to  
384 each tumor.

385

386

387 Finally, we report that the infiltration of T cell clones during NAC leads to an enrichment in  
388 the TCR repertoire of post-NAC samples, either derived from the contralateral tumor, either  
389 arising in both bilateral tumors with residual disease. At a time where bilateral tumor contexts

390 represent a model of growing interest to understand mechanisms underlying immune response  
391 to anticancer treatment in mice <sup>31, 38</sup>, we provide human data regarding the temporal analysis  
392 of the TCR repertoire in sBBCs.

393

394 Our study has several strengths. We analyzed genomic and transcriptomic data with modern  
395 technologies. Whole exome sequencing is more informative than targeted sequencing for  
396 determining clonal relationships, as it enables the comprehensive identification of mutations  
397 present in both breast cancers in genomic locations that were not included in the sequencing  
398 panel. Whole genome sequencing could further identify mutations in non-coding regions of  
399 the genome. Second, we studied a rare and unique cohort of patients, enabling direct  
400 comparison of left *versus* right PT together with a temporal analysis comparing paired  
401 samples before *versus* after NAC. Hence, beyond all the challenges in analyzing tumor  
402 evolution from bulk sequencing data <sup>39</sup>, we were able to leverage multiple tumor samples to  
403 reconstruct a clonal phylogeny from germline data to left and right sBBCs both before and  
404 after treatment. Third, to our knowledge, our data on immune infiltration are novel  
405 contributions to the literature and provide insights into the immune mechanisms underlying  
406 the biology of sBBCs. This study also has limitations. First, we were only able to sequence a  
407 limited number of cases. We cannot eliminate the possibility that a subset of clonally related  
408 sBBCs could be identified if larger cohorts were sequenced. Second, the cohort was enriched  
409 in patients with *BRCA* mutations (although this was not an inclusion criteria), and the latter  
410 might represent tumors with particular biological patterns. Recent studies suggest however  
411 that the proportion of BBC patients harboring germline pathogenic variants in cancer  
412 susceptibility genes may represent up to one third of the patients <sup>40</sup>. Finally, characterization  
413 of the immune microenvironment by bulk sequencing approaches has inherent limitations and  
414 new insights could be generated by single cell technologies.

415

416 To conclude, our data suggest that the similarity of molecular portraits in sBBCs derives from  
417 common environmental factors but not from genetic clonal alterations. Both tumor immune  
418 infiltration and response to treatment are influenced by the presence of a contralateral tumor.  
419 Pairs of tumors from different BC subtypes should be considered as singular entities before  
420 primary systemic treatment is considered as observed responses might deviate from well-  
421 known profiles of response to chemotherapy.

422

## 423 **Material and methods**

### 424 *Patients and treatments*

425 We identified a cohort of 17575 patients with non-metastatic BC treated at the Institut Curie  
426 (Paris and Saint Cloud, France) between 2005 and 2015 in the institutional database (CNIL  
427 number 1766392 - v1). Patients were treated according to local guidelines. When indicated,  
428 chemotherapy was administered in a neoadjuvant or adjuvant setting, endocrine therapy was  
429 indicated in the case of positivity for hormone receptor and according to prognostic factors,  
430 and patients with *HER2*-positive tumors received neoadjuvant and/or adjuvant trastuzumab  
431 from 2007 onwards. This study was approved by the Breast Cancer Study Group and by the  
432 Institutional Review Board of Institut Curie and was conducted in accordance with  
433 institutional and ethical rules regarding research on tissue specimens and patients.  
434 Synchronous bilateral breast cancers (sBBCs) were defined as the occurrence of primary  
435 tumors occurring in both breasts with a time interval no greater than 6 months. Metachronous  
436 BCs defined as a time interval greater than 6 months between the diagnoses of the first and  
437 second tumours were not included in the current study. Patients with exclusive in situ  
438 carcinoma (DCIS) in one of the two sides were excluded from the analyses.

439

### 440 *Tumor samples and BC subtype*

441 In accordance with guidelines used in France<sup>41</sup>, cases were considered estrogen receptor (ER)  
442 or progesterone receptor (PR) positive if at least 10% of the tumor cells expressed estrogen  
443 and/or progesterone receptors (ER/PR). *HER2* expression was determined by  
444 immunohistochemistry with scoring in accordance with American Society of Clinical  
445 Oncology (ASCO)/College of American Pathologists (CAP) guidelines<sup>42</sup>. Scores 3+ were  
446 reported as positive, score 1+/0 as negative (-). Tumors with scores 2+ were further tested by  
447 FISH. *HER2* gene amplification was defined in accordance with ASCO/CAP guidelines. BC  
448 subtypes were defined as follows: tumors positive for either ER or PR, and negative for *HER2*  
449 were classified as luminal; tumors positive for *HER2* were considered to be *HER2*-positive BC;  
450 tumors negative for ER, PR, and *HER2* were considered to be triple-negative breast cancers  
451 (TNBC).

452

### 453 *Pathological review*

454 Bulk tumor specimens - and the corresponding pretreatment core needle biopsy specimens in  
455 case of neoadjuvant treatment - were reviewed by an expert in breast pathology (ML). All  
456 tumoral tissues studied were Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples. In



457 the cases with bilateral invasive carcinoma, tumor infiltrating lymphocytes (TILs) were  
458 reviewed specifically for the purposes of this study, between September 2016 to March 2017.  
459 In accordance with the recommendations of the international TILs Working Group<sup>43</sup>, we  
460 checked for presence of a mononuclear cell infiltrate in the stroma on hematoxylin and eosin-  
461 stained sections without additional staining, after excluding areas around ductal carcinomas *in*  
462 *situ* (DCIS), and tumor zones with necrosis and artifacts. Infiltrates were scored on a  
463 continuous scale, as the mean percentage of the stromal area occupied by mononuclear cells.  
464 Intratumoral TILs (IT TILs) were defined as intraepithelial mononuclear cells within tumor  
465 nests or in direct contact with tumor cells and stromal TILs (Str TILs) were defined as  
466 mononuclear inflammatory cells within intratumoral stromal area and were reported as  
467 percentage of stromal area. After NAC, we assessed TIL levels within the borders of the  
468 residual tumor bed, as defined by the RCB and recommended by the TILs working group<sup>44</sup>.  
469 We simultaneously determined the RCB index, as described by Symmans index<sup>45</sup>, with the  
470 web-based calculator freely available via the Internet  
471 ([www.mdanderson.org/breastcancer\\_RCB](http://www.mdanderson.org/breastcancer_RCB)). We defined pathological complete response  
472 (pCR) as the absence of invasive residual tumor from both the breast and axillary nodes  
473 (ypT0/is N0).

474

#### 475 ***Concordance between the tumors of sBBCs pairs***

476 We evaluated the concordance of the clinical and pathological characteristics between the two  
477 tumors within the same patient. Pairs of sBBCs composed of tumors of the same BC subtypes  
478 were classified as concordant and where otherwise classified as discordant.

479

#### 480 ***Sample's preparation and next generation sequencing (NGS) analyses***

481 DNA and RNA were obtained from the Biological Resource Center (BRC of Institut Curie).  
482 After selecting patients treated with NAC, tumors from whom sufficient frozen material from  
483 both left and right tumors was available in the institutional tissue bank both before (defined as  
484 primary tumor (PT)) and after treatment in case of residual disease (RD) were included.  
485 Fresh-frozen samples were subjected to genomic DNA extraction and DNA qualification  
486 using QuBit system.

487

#### 488 ***Whole exome sequencing***



489 1µg of genomic DNA from each sample were subjected to shearing using Covaris system and  
490 Illumina compatible libraries were performed according to Agilent SureSelect XT2 library  
491 protocol consisting in repairing DNA ends and ligating Illumina barcoded adapters followed  
492 by a PCR amplification. Libraries were pooled in equimolar condition before being  
493 hybridized on dedicated biotinylated RNA probes targeting whole exome sequences (Agilent  
494 Human all Exon V5 capture probes). After selection using streptavidin beads and PCR  
495 amplification, enriched library pools were subjected to qPCR quantification using the KAPA  
496 library quantification kit (Roche). Sequencing was carried out on the HiSeq2000 instrument  
497 from Illumina based on a 2 x 100 cycles mode (paired-end reads, 100 bases) using high output  
498 flow cells to produce over 50 and 170 million paired-end reads for 30X (germline) and 100X  
499 (tumors) respectively. Samples were sequenced to a median depth of coverage of 153 reads,  
500 with 95 % of exonic bases passing 50×coverage. 2 samples were discarded from the analysis  
501 due to low purity (RD4\_R and RD6B\_R). Reads were aligned on the human genome  
502 reference hg19/GRCh37 by Burrows-Wheeler Aligner <sup>46</sup>v0.7.5a; filtering of reads based on  
503 target intersection, mapping quality and PCR duplicates removal, using Picard<sup>47</sup>, Bedtools<sup>48</sup>  
504 and Samtools<sup>49</sup>, and preprocess using GATK<sup>50</sup> for local realignment around indels, and base  
505 score recalibration. Preliminary variant calling was performed using Mutect2<sup>51</sup> for tumor  
506 samples, and haplotype caller<sup>52</sup> for normal samples. SuperFreq v. 1.3.2<sup>53</sup> performed  
507 annotation and filtering of somatic indels and SNVs, copy number and purity estimation, and  
508 subclonal reconstruction. SuperFreq was run to analyze together the samples of the same side  
509 for each patient. We performed an additional filtering of alterations present in either dbSNP<sup>54</sup>  
510 or ExAC<sup>55</sup> at a frequency greater than 0.2 or after manual review of the alignment on the  
511 Integrative Genomics Viewer (IGV)<sup>56</sup> or a Somatic Score computed by SuperFreq greater  
512 than 0.5. Due to insufficient purity, 2 samples were discarded from the analyses (RD4\_R and  
513 RD6B\_R).

514

#### 515 *Somatic mutations interpretation*

516 Somatic variants were annotated using VEP (version 104) <sup>57</sup>. A variant was denoted as driver  
517 if the mutation was present as either as a splice site, a nonsense, a frameshift or a non-  
518 synonymous SNV or indel in COSMIC census gene<sup>58</sup>. The percentage of shared mutations in  
519 pairs (pair left right; pair PT-RD; pair of two multicentric tumors of the same side) was  
520 defined as the intersect between the mutations present in both tumors \*2 divided by the sum  
521 of the mutation in the two tumors of the pair \*100.

522

523 *Mutational signature deconvolution*

524

525 The contribution of mutational signatures to individual tumor samples were explored using  
526 the signatures deconvoluted by Alexandrov *et al.*<sup>27</sup> and referenced in the Cosmic database<sup>59</sup>.  
527 We restricted the analyses to the 13 signatures previously evidenced in BC. Signature  
528 activities were estimated using the decompTumor2Sig algorithm<sup>60</sup> in the musicatk (version  
529 1.0.0) R package<sup>61</sup>. The percentage of mutational signatures was calculated by summing the  
530 relative contribution of each signature in PT samples to the whole tumor spectrum, divided by  
531 the number of sampled and the result was multiplied by 100. To avoid overrepresentation of  
532 the patient #6 to the cohort and because signatures profiles were similar on each side, we  
533 averaged the values of the left side on the one hand, and the values of the right side on the  
534 other hand.

535

536 *RNA sequencing*

537 Total RNA extracts from tumor samples were subjected to quality control on a Bioanalyzer  
538 instrument and only RNA with RIN (RNA Integrity Number) > 7 were used for sequencing.  
539 RNA quantification was achieved using absorbance at 260nm with a Nanodrop  
540 spectrophotometer. RNA sequencing libraries were prepared from 1 µg of total RNA using  
541 the Illumina TruSeq Stranded mRNA Library preparation kit (following provider's  
542 instructions) which allows performing a strand-specific sequencing. Briefly, a first step of  
543 polyA+ RNA selection using oligodT magnetic beads is done to focus sequencing on  
544 polyadenylated transcripts. After fragmentation, cDNA synthesis was performed and resulting  
545 fragments were used for dA-tailing and then ligated to the TruSeq indexed adapters. PCR  
546 amplification is finally achieved to create the final cDNA library. After qPCR quantification  
547 using the KAPA library quantification kit (Roche), sequencing was carried out using 2 x 100  
548 cycles (paired-end reads 100 bases). Sequencing was performed by multiplexing barcoded  
549 libraries on with the Illumina HiSeq2000 instrument using high output flow cells to obtain  
550 100 million paired-end reads per sample. Alignments were performed on human reference  
551 sequences using TopHat<sup>62</sup> v.2.0.621. Reads with mapping quality <20 and reads marked as  
552 duplicates by Picard v.1.97 were excluded from further analysis. Gene- level read counts were  
553 obtained using HTSeq-count<sup>63</sup> and RefSeq hg19/GRCh37.

554

555 *Selection of the genes with the most variant expression and clustering*

556 We selected the most variant genes, based on the inflection point of the interquartile range  
557 (IQR) distribution for gene expression. The gene expression was previously rlog transformed  
558 with DESeq2<sup>64</sup>. This method is more data-driven than a fixed threshold to define the  
559 proportion of genes with the highest level of variation. For each gene, we applied the  
560 following procedure: (1) we calculated the IQR for all samples; (2) we sorted the IQR values  
561 of the genes in ascending order, to generate an ordered distribution; (3) we estimated the  
562 major inflection point of the IQR curve as the point on the curve furthest away from a line  
563 drawn between the start and end points of the distribution; (4) we retained genes with an IQR  
564 higher than the inflection point. Hierarchical clustering was performed with Pearson distance  
565 and Ward linkage.

566

#### 567 *Statistical analysis*

568 The study population was described in terms of frequencies for qualitative variables, or  
569 medians and associated ranges for quantitative variables. Chi-squared tests were performed to  
570 search for differences between subgroups for each variable (considered significant for  $p$ -  
571 values  $\leq 0.05$ ). Continuous variables were compared between groups in Wilcoxon–Mann–  
572 Whitney tests for groups of fewer than 30 patients and for variables following multimodal  
573 distributions. Student’s t-tests were used in all other cases. Pre and post-NAC TIL levels were  
574 analyzed as continuous variables. In case of categorical variables, the kappa coefficient<sup>65</sup>  
575 was computed as a measure of concordance between the left and the right side of a same  
576 patient (varying from - 1 as absolute discordance, to + 1 as absolute concordance, 0 as  
577 absence of concordance); otherwise in case of numeric or integer variables, the kendall test  
578 was used.

579 All  $P$ -values no greater than 0.05 were considered significant. In the case where we tested the  
580 hypothesis of potentially different effects of the concordant or discordant status of the tumor  
581 pair regarding BC subtype on immune infiltration or response to treatment, we included an  
582 interaction term in a linear regression model or logistic regression model respectively. A  $p$ -  
583 value of 0.10 was selected to determine the statistical significance of the interaction term, as it  
584 has been suggested due to a low power of the test in the interaction setting<sup>66</sup>. When applicable,  
585 all statistical tests were two-sided. In boxplots, lower and upper bars represent the first and  
586 third quartile, respectively, the  
587 medium bar is the median, and whiskers extend to 1.5 times the inter-quartile range. Data  
588 were processed and statistical analyses were carried out with R software version 3.1.2  
589 ([www.cran.r-project.org](http://www.cran.r-project.org)).

590

591 *Data availability statement*

592 The genomic and transcriptomic data generated during the current study are available in the  
593 European genome phenome archive repository, [PERSISTENT WEB LINK TO  
594 DATASETS].

595

596

597 *CIBERSORT*

598 CIBERSORT is an analytical tool quantifying the levels of distinct immune cell types within  
599 a complex gene expression mixture (<https://cibersort-stanford-edu.proxy.insermbiblio.inist.fr>).  
600 We applied the original CIBERSORT gene signature LM22 defining 22 immune cell subtypes  
601 to all the samples of the cohort, the number of permutations being set to 100, and the mode  
602 being set to “absolute”. For each immune subpopulation, (i) we calculated the difference  
603 between a given sample and the rest of the cohort; (ii) we squared the result; (iii) and we  
604 summed the difference between this patient and each other sample of the cohort, resulting in a  
605 dissimilarity index. We displayed the overall results on a correlogram.

606

607 *TCR-sequencing analysis.*

608 We applied the MixCR algorithm on RNASeq data of 20 samples to identify and quantify  
609 TCR Beta-chain CDR3 sequences. MiXCR (version 2.1.5) <sup>67</sup>was used with its default  
610 parameters to extract and quantify TCR b-chain CDR3 sequences from RNA-seq fastq files.  
611 From the MiXCR output, we obtained for each sample the total number of distinct TCRb  
612 clones and the number of reads supporting each clone, and we normalized the result by the  
613 total number of reads. We investigated if TCR sequences identified by MixCR were identified  
614 in the VDJDB database, a curated database of T-cell receptor sequences of known antigen  
615 specificity<sup>68</sup> (Details available at the following URL : [https://github.com/antigenomics/vdjdb-](https://github.com/antigenomics/vdjdb-db)  
616 db)

617

618 **Acknowledgments**

619 We thank Corinne Azrijev for collecting patient's consents, Celine Meaudre for the  
620 management of the samples, Audrey Rapinat for DNA and RNA extraction, Antoine Mader  
621 for help in designing the figures, Lounes Djerroudi for his advice.

622 **Author's contributions**

623 FR and ASHP designed and conceptualized the study.  
624 LD, MD, EL and ASHP identified the Curie cohort and the patient tumor samples.  
625 ASHP and LD managed the clinical database, including performing retrospective chart  
626 review.  
627 OM, SV, and MA provided patient tumor samples.  
628 ML provided pathology support and performed pathological review and TILs scoring with TL  
629 and BG.  
630 FZ, JA and JH performed literature review.  
631 IB, JYP provided scientific advice and expert guidance on tumor biology.  
632 JA, CL, CV, and ASHP performed the whole exome sequencing analyses.  
633 BS and ASHP performed the RNASeq analyses.  
634 WR provided guidance for MixCR analyses.  
635 JW provided scientific direction.  
636 FR and ASHP allocated funding.  
637 All the authors participated in the preparation of the manuscript.  
638  
639  
640

641 **References**

642

- 643 1. Chen, Y., Thompson, W., Semenciw, R. & Mao, Y. Epidemiology of contralateral breast  
644 cancer. *Cancer Epidemiol. Biomarkers Prev.* **8**, 855–861 (1999).
- 645 2. Hartman, M. *et al.* Incidence and prognosis of synchronous and metachronous bilateral  
646 breast cancer. *J. Clin. Oncol.* **25**, 4210–4216 (2007).
- 647 3. Vuoto, H. D. *et al.* Bilateral breast carcinoma: clinical characteristics and its impact on  
648 survival. *Breast J* **16**, 625–632 (2010).
- 649 4. Sakai, T. *et al.* National trends of synchronous bilateral breast cancer incidence in the  
650 United States. *Breast Cancer Res. Treat.* (2019) doi:10.1007/s10549-019-05363-0.
- 651 5. Carmichael, A. R., Bendall, S., Lockerbie, L., Prescott, R. & Bates, T. The long-term  
652 outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral  
653 tumours. *Eur J Surg Oncol* **28**, 388–391 (2002).
- 654 6. Kheirelseid, E. A. H. *et al.* Bilateral breast cancer: analysis of incidence, outcome,  
655 survival and disease characteristics. *Breast Cancer Res. Treat.* **126**, 131–140 (2011).
- 656 7. Daly, M. B. *et al.* NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment:  
657 Breast, Ovarian, and Pancreatic, Version 1.2020. *J Natl Compr Canc Netw* **18**, 380–391  
658 (2020).
- 659 8. Brommesson, S. *et al.* Tiling array-CGH for the assessment of genomic similarities  
660 among synchronous unilateral and bilateral invasive breast cancer tumor pairs. *BMC Clin*  
661 *Pathol* **8**, 6 (2008).
- 662 9. Chunder, N., Roy, A., Roychoudhury, S. & Panda, C. K. Molecular study of clonality in  
663 multifocal and bilateral breast tumors. *Pathol Res Pract* **200**, 735–741 (2004).
- 664 10. Imyanitov, E. N. *et al.* Concordance of allelic imbalance profiles in synchronous and  
665 metachronous bilateral breast carcinomas. *Int J Cancer* **100**, 557–564 (2002).

- 666 11. Janschek, E. *et al.* Contralateral breast cancer: molecular differentiation between  
667 metastasis and second primary cancer. *Breast Cancer Res Treat* **67**, 1–8 (2001).
- 668 12. Shibata, A. *et al.* Clonal analysis of bilateral breast cancer. *Clinical Cancer Research* **2**,  
669 743–748 (1996).
- 670 13. Song, F. *et al.* Comparative genomic analysis reveals bilateral breast cancers are  
671 genetically independent. *Oncotarget* **6**, 31820–31829 (2015).
- 672 14. Teixeira, M. R. *et al.* Assessment of clonal relationships in ipsilateral and bilateral  
673 multiple breast carcinomas by comparative genomic hybridisation and hierarchical  
674 clustering analysis. *British Journal of Cancer* **91**, 775–782 (2004).
- 675 15. Noguchi, S. *et al.* Discrimination between multicentric and multifocal carcinomas of the  
676 breast through clonal analysis. *Cancer* **74**, 872–877 (1994).
- 677 16. Stenmark-Askmal, M., Gentile, M., Wingren, S. & Ståhl, O. Protein accumulation and  
678 gene mutation of p53 in bilateral breast cancer. South-East Sweden Breast Cancer Group.  
679 *Acta Oncol* **40**, 56–62 (2001).
- 680 17. Teixeira, M. R. *et al.* Discrimination between multicentric and multifocal breast  
681 carcinoma by cytogenetic investigation of macroscopically distinct ipsilateral lesions.  
682 *Genes Chromosomes Cancer* **18**, 170–174 (1997).
- 683 18. Ghazani, A. A. *et al.* Genomic alterations in sporadic synchronous primary breast cancer  
684 using array and metaphase comparative genomic hybridization. *Neoplasia* **9**, 511–520  
685 (2007).
- 686 19. Begg, C. B. *et al.* Contralateral breast cancers: Independent cancers or metastases? *Int. J.*  
687 *Cancer* **142**, 347–356 (2018).
- 688 20. Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic  
689 properties of tumors associated with local immune cytolytic activity. *Cell* **160**, 48–61  
690 (2015).

- 691 21. Loi, S. *et al.* RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating  
692 Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK  
693 and PD-1/PD-L1 Immune Checkpoint Inhibitors. *Clin. Cancer Res.* **22**, 1499–1509  
694 (2016).
- 695 22. Fish, E. N. The X-files in immunity: sex-based differences predispose immune responses.  
696 *Nat. Rev. Immunol.* **8**, 737–744 (2008).
- 697 23. Lazuardi, L. *et al.* Age-related loss of naïve T cells and dysregulation of T-cell/B-cell  
698 interactions in human lymph nodes. *Immunology* **114**, 37–43 (2005).
- 699 24. Denkert, C. *et al.* Tumor-associated lymphocytes as an independent predictor of response  
700 to neoadjuvant chemotherapy in breast cancer. *J. Clin. Oncol.* **28**, 105–113 (2010).
- 701 25. Denkert, C. *et al.* Tumor-infiltrating lymphocytes and response to neoadjuvant  
702 chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-  
703 positive and triple-negative primary breast cancers. *J. Clin. Oncol.* **33**, 983–991 (2015).
- 704 26. Denkert, C. *et al.* Tumour-infiltrating lymphocytes and prognosis in different subtypes of  
705 breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet*  
706 *Oncol.* **19**, 40–50 (2018).
- 707 27. Alexandrov, L. B. *et al.* The repertoire of mutational signatures in human cancer. *Nature*  
708 **578**, 94–101 (2020).
- 709 28. Russnes, H. G. *et al.* Paired distribution of molecular subtypes in bilateral breast  
710 carcinomas. *Cancer Genet* **204**, 96–102 (2011).
- 711 29. de la Rochefordiere, A. *et al.* Simultaneous bilateral breast carcinomas: a retrospective  
712 review of 149 cases. *International Journal of Radiation Oncology, Biology, Physics* **30**,  
713 35–41 (1994).



- 714 30. Kim, H. *et al.* Distribution of tumor subtypes in bilateral breast cancer: Comparison  
715 between synchronous and metachronous cancer. *Asia Pac J Clin Oncol* (2020)  
716 doi:10.1111/ajco.13444.
- 717 31. Chen, I. X. *et al.* A bilateral tumor model identifies transcriptional programs associated  
718 with patient response to immune checkpoint blockade. *Proc Natl Acad Sci U S A* **117**,  
719 23684–23694 (2020).
- 720 32. Pak, L. M. *et al.* Tumor phenotype and concordance in synchronous bilateral breast  
721 cancer in young women. *Breast Cancer Res Treat* **186**, 815–821 (2021).
- 722 33. Beinart, G. *et al.* Clinical course of 771 patients with bilateral breast cancer:  
723 characteristics associated with overall and recurrence-free survival. *Clin. Breast Cancer* **7**,  
724 867–874 (2007).
- 725 34. Mosbah, R. *et al.* Pathological Characteristics of Both Tumors in Bifocal and Bicentric  
726 Breast Cancer. *Anticancer Res* **35**, 5111–5116 (2015).
- 727 35. Hartman, M. *et al.* Genetic implications of bilateral breast cancer: a population based  
728 cohort study. *Lancet Oncol.* **6**, 377–382 (2005).
- 729 36. Goto, R. *et al.* The number of FoxP3-positive tumor-infiltrating lymphocytes in patients  
730 with synchronous bilateral breast cancer. *Breast Cancer* **27**, 586–593 (2020).
- 731 37. Reinisch, M. *et al.* pCR rates in patients with bilateral breast cancer after neoadjuvant  
732 anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual  
733 patients data of four German neoadjuvant trials. *Breast (Edinburgh, Scotland)* **32**, 73–78  
734 (2017).
- 735 38. Tsunoda, M. *et al.* T cell receptor (TCR) repertoire analysis reveals a highly conserved  
736 TCR repertoire in a bilateral tumor mouse model. *bioRxiv* 2021.05.13.443732 (2021)  
737 doi:10.1101/2021.05.13.443732.

- 738 39. Tarabichi, M. *et al.* A practical guide to cancer subclonal reconstruction from DNA  
739 sequencing. *Nat Methods* **18**, 144–155 (2021).
- 740 40. Fanale, D. *et al.* Detection of Germline Mutations in a Cohort of 139 Patients with  
741 Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in  
742 Other Genes beyond BRCA1/2. *Cancers (Basel)* **12**, E2415 (2020).
- 743 41. GEFPICS-FNCLCC. [Recommendations for the immunohistochemistry of the hormonal  
744 receptors on paraffin sections in breast cancer. Update 1999. Group for Evaluation of  
745 Prognostic Factors using Immunohistochemistry in Breast Cancer (GEFPICS-FNCLCC)].  
746 *Ann Pathol* **19**, 336–343 (1999).
- 747 42. Wolff, A. C. *et al.* American Society of Clinical Oncology/College of American  
748 Pathologists guideline recommendations for human epidermal growth factor receptor 2  
749 testing in breast cancer. *J. Clin. Oncol.* **25**, 118–145 (2007).
- 750 43. Salgado, R. *et al.* The evaluation of tumor-infiltrating lymphocytes (TILs) in breast  
751 cancer: recommendations by an International TILs Working Group 2014. *Ann. Oncol.* **26**,  
752 259–271 (2015).
- 753 44. Dieci, M. V. *et al.* Update on tumor-infiltrating lymphocytes (TILs) in breast cancer,  
754 including recommendations to assess TILs in residual disease after neoadjuvant therapy  
755 and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker  
756 Working Group on Breast Cancer. *Semin. Cancer Biol.* **52**, 16–25 (2018).
- 757 45. Symmans, W. F. *et al.* Measurement of residual breast cancer burden to predict survival  
758 after neoadjuvant chemotherapy. *J. Clin. Oncol.* **25**, 4414–4422 (2007).
- 759 46. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler  
760 transform. *Bioinformatics* **25**, 1754–1760 (2009).
- 761 47. Picard Tools - By Broad Institute. <https://broadinstitute.github.io/picard/>.

- 762 48. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing  
763 genomic features. *Bioinformatics* **26**, 841–842 (2010).
- 764 49. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**,  
765 2078–2079 (2009).
- 766 50. McKenna, A. *et al.* The Genome Analysis Toolkit: A MapReduce framework for  
767 analyzing next-generation DNA sequencing data. *Genome Res* **20**, 1297–1303 (2010).
- 768 51. Cibulskis, K. *et al.* Sensitive detection of somatic point mutations in impure and  
769 heterogeneous cancer samples. *Nat. Biotechnol.* **31**, 213–219 (2013).
- 770 52. Poplin, R. *et al.* Scaling accurate genetic variant discovery to tens of thousands of  
771 samples. *bioRxiv* 201178 (2018) doi:10.1101/201178.
- 772 53. Flensburg, C., Sargeant, T., Oshlack, A. & Majewski, I. J. SuperFreq: Integrated mutation  
773 detection and clonal tracking in cancer. *PLoS Comput. Biol.* **16**, e1007603 (2020).
- 774 54. Sherry, S. T. *et al.* dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res* **29**,  
775 308–311 (2001).
- 776 55. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**,  
777 285–291 (2016).
- 778 56. Robinson, J. T. *et al.* Integrative genomics viewer. *Nat Biotechnol* **29**, 24–26 (2011).
- 779 57. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biology* **17**, 122  
780 (2016).
- 781 58. Sondka, Z. *et al.* The COSMIC Cancer Gene Census: describing genetic dysfunction  
782 across all human cancers. *Nat Rev Cancer* **18**, 696–705 (2018).
- 783 59. Forbes, S. A. *et al.* COSMIC: somatic cancer genetics at high-resolution. *Nucleic Acids*  
784 *Res* **45**, D777–D783 (2017).
- 785 60. Krüger, S. & Piro, R. M. decompTumor2Sig: identification of mutational signatures  
786 active in individual tumors. *BMC Bioinformatics* **20**, 152 (2019).

- 787 61. Chevalier, A. *et al.* *The Mutational Signature Comprehensive Analysis Toolkit (musicatk)*  
788 *for the discovery, prediction, and exploration of mutational signatures.*  
789 2020.11.17.385864 <https://www.biorxiv.org/content/10.1101/2020.11.17.385864v2>  
790 (2021) doi:10.1101/2020.11.17.385864.
- 791 62. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient  
792 alignment of short DNA sequences to the human genome. *Genome Biology* **10**, R25  
793 (2009).
- 794 63. Anders, S., Pyl, P. T. & Huber, W. HTSeq A Python framework to work with high-  
795 throughput sequencing data. *Bioinformatics* **31**, 166–169 (2014).
- 796 64. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion  
797 for RNA-Seq data with DESeq2. *bioRxiv* 1–21 (2014) doi:10.1101/002832.
- 798 65. Fleiss J., H. *Statistical Methods for Rates and Proportions. WILEY SERIES IN*  
799 *PROBABILITY AND STATISTICS* **16**, 539–539 (2003).
- 800 66. Selvin. *Statistical analysis of epidemiologic data.* (Oxford University Press, 1991).
- 801 67. Bolotin, D. A. *et al.* MiXCR: software for comprehensive adaptive immunity profiling.  
802 *Nat Methods* **12**, 380–381 (2015).
- 803 68. Bagaev, D. V. *et al.* VDJdb in 2019: database extension, new analysis infrastructure and a  
804 T-cell receptor motif compendium. *Nucleic Acids Research* **48**, D1057–D1062 (2020).
- 805 69. Newman, A. M. *et al.* Robust enumeration of cell subsets from tissue expression profiles.  
806 *Nat. Methods* **12**, 453–457 (2015).
- 807

808

## 809 **Figures and tables legends**

810 **Fig1: Tumor's characteristics of the pairs of sBBCs included in the cohort.** Tumor's  
811 characteristics are based on the 302 pairs with concordance subtype available out of 313 pairs.  
812 The concordance refers to the status of both tumors within a pair of sBBCs regarding BC  
813 subtype, either of the same BC subtype (tumor in concordant pair), either of different BC  
814 subtypes (tumor in discordant pair). A. Repartition of the association of the BC subtypes  
815 within a pair of sBBCs according to the concordance or the discordance status of the pair; B.  
816 ER staining intensity of the index tumor by the concordance status of the pair it belongs to  
817 (luminal tumors only, n=510); C. PR staining intensity of the index tumor by the  
818 concordance status of the pair it belongs to (luminal tumors only, n=446); D. Str TIL levels of  
819 the index tumor by BC subtype and by the concordance status of the pair it belongs to; E. IT  
820 TIL levels of the index tumor by BC subtype and by the concordance status of the pair it  
821 belongs to; F. pCR rates of the index tumor by BC subtype and by the concordance status of  
822 the pair it belongs to; G. Evolution of the 100 tumors after NAC according to the BC subtype  
823 of the index tumor and by the concordance status of the pair of tumor.  
824 Abbreviations: BC, breast cancer; ER, estrogen receptor; IT TIL, intra tumoral tumor  
825 infiltrating lymphocytes. NAC, neoadjuvant chemotherapy; pCR, pathologic complete  
826 response; PR, progesterone receptor; sBBC, synchronous bilateral breast cancers; Str TIL,  
827 stromal tumor infiltrating lymphocytes; TNBC, triple negative breast cancer  
828

## 829 **Fig2: Tumor mutation profiles**

830 The analyses are performed in the in left, right, pre and post-NAC samples of a cohort of 6  
831 patients (20 samples) with next generation sequencing data available. A. Heatmap of somatic  
832 driver mutations (including missense, nonsense, and splicing) detected in 6 study patients and  
833 20 samples. B. Venn diagrams showing the number of mutations shared between the left  
834 (pink) and the right (purple) primary tumors of a same patient; and shared (intersect  
835 turquoise) between the PT (light green) and the corresponding specimen after NAC (RD,  
836 residual disease, blue). The post NAC samples RD4\_R and RD6B\_R were discarded due to  
837 poor sample purity. Mutations from the 2 multicentric tumors of each side of patient #6 have  
838 been merged.  
839 Abbreviations: L, left; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response;  
840 PT, primary tumor; R, right; RD, residual disease; TNBC, triple negative breast cancer  
841

## 842 **Fig3: Copy number alterations (CNA) and mutational signatures profiles.**

843 The analyses are performed in the in left, right, pre and post-NAC samples of a cohort of 6  
844 patients (20 samples) with next generation sequencing data available. Mutational signatures  
845 published by Alexandrov<sup>27</sup> are calculated using the deconstructSigs package. A. CNA are  
846 compared among the two sides of the primary tumor of the same patient; B. Among the  
847 primary tumor and its corresponding sample with RD after NAC.  
848 C. Mutational signatures are compared among the two sides of the primary tumor of the same  
849 patient (Mutations from the 2 multicentric tumors of each side of patient #6 have been  
850 merged.) and; D. Among the primary tumor and its corresponding sample with RD after  
851 NAC.  
852 Abbreviations: BC, breast cancer; CAN, copy number alterations; CH-LOH, copy-neutral loss  
853 of heterozygosity; chr, chromosome; L, left; NAC, neoadjuvant chemotherapy; R, right; RD,  
854 residual disease  
855

856 **Fig4: Fishplot retracing phylogeny between left, right primary tumors and**  
857 **corresponding residual disease.**

858 Each subfigure represents the evolution of the tumors of a given patient under NAC. The  
859 upper fish plot represents the evolution of the left tumor(s), the lower fishplot represents the  
860 evolution of the right tumor(s). Each fishplot displays the prevalence of subclones throughout  
861 treatment. Subclonal architecture was reconstructed with SuperFreq. Subclonal profiles show  
862 annotated common driver cancer genes. A. Both PTs were mutated for P53, but the genomic  
863 alteration was different on the left and the right side (right side: indel frameshift deletion  
864 position 7578213; left side: substitution C>T p.R175C missense substitution identified as  
865 pathogenic in Clinvar, and present in the RD); B. Both tumors were mutated for TP53 with 2  
866 different mutations Both tumors were mutated for TP53 with 2 different mutations (right side:  
867 frameshift loss of a nucleotide position 7577558; E. TP53 was mutated on both sides (left  
868 side: frameshift deletion position 7578213, right side: frameshift deletion position 7579522);  
869 Abbreviations: NAC, neoadjuvant chemotherapy; PT, primary tumor; RD, residual disease.  
870






871 **Fig5: Genomic alterations in the patient with multicentric sBBCs.**

872 The analyses are performed in the in two left tumors (PT6A\_L – PT6B\_L), and in the 2 right  
873 tumors (PT6A\_R – PT6B\_R). The sample with residual disease (RD6B\_R) was discarded due  
874 to poor sample purity. A. Tumor mutation profiles: Venn diagrams showing the number of  
875 mutations shared between the 2 primary tumors of each side (yellow intersect); B. Copy  
876 number alterations (CNA) profiles, compared among the two multicentric tumors of each  
877 side; C. Mutational signatures as from Alexandrov<sup>27</sup> compared among the two multicentric  
878 tumors of each side; D. Fishplot retracing the phylogeny between the two multicentric tumors  
879 of each side. Each fish plot can be interpreted from the left to the right, or from the right to the  
880 left, corresponding to the emergence or the extinction of a clone respectively.  
881 Abbreviations: L, left; PT, primary tumor; R, right; RD, residual disease; BC, breast cancer;  
882 CAN, copy number alterations; CH-LOH, copy-neutral loss of heterozygosity; chr,  
883 chromosome.  
884

885 **Fig6: Repartition of the shared clonal TCR repertoire assessed by TCR Beta-chain**  
886 **CDR3 sequences among samples at the individual patient level.**


887 The clonotypes are identified with the MixCR algorithm<sup>67</sup>. Only the TCR sequences shared  
888 within different samples of a same patient are displayed on the figure. Unique clonotypes  
889 (n=5994) and clonotypes shared between patients of the cohort (n=32) are not displayed on  
890 the figure. The upper panel represents the repartition of the clonotypes in the 14 PT of the  
891 patients #1 to #6, and the lower panel represents the repartition of clonotypes of the 6 samples  
892 with RD.

893 Abbreviations: L, left; PT, primary tumor; R, right; RD, residual disease TCR: T cell receptor.  
894  
895






Pinteraction BC subtype and concordance status on str TILs=0.57

Pinteraction BC subtype and concordance status on IT TILs=0.0006












Pinteraction between BC subtype and concordance status=0.07











**A Patient #1****B Patient #2****C Patient #3****D Patient #4****E Patient #5**


A



B



C



SBS1 SBS2 SBS3 SBS5 SBS8 SBS9 SBS13 SBS17a SBS17b SBS18 SBS37 SBS40 SBS41

D

